Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice

Drugs: Education, Prevention and Policy

Volumn 14, Issue 1, 2007, Pages 61-74

  Treloar, Carla ^a   Fraser, Suzanne ^a   Valentine, Kylie ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Consumer involvement; Opoid pharmacotherapy; Takeaway doses

Indexed keywords

EID: 33847081715     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.1080/09687630600997527     Document Type: Article

References (38)

1. Australian Injecting & Illicit Drug Users League (2004). Policy position consumer representation. Canberra, Australia: Australian Injecting & Illicit Drug Users League.
2. Bell, J., Dru, A., Fischer, B., Levit, S., & Sarfraz, M. (2002). Substitution therapy for heroin addiction. Substance Use and Misuse, 37, 1149-1178.
3. Boeri, M. (2004). 'Hell, I'm an addict, but I ain't no junkie': An ethnographic analysis of aging heroin users.' Human Organization, 63(2), 236-245.
4. Canadian HIV/AIDS Legal Network (2005). 'Nothing about us without us', greater, meaningful involvement of people who use illegal drugs: A public health, ethical, and human rights imperative. Toronto, Canada: Canadian HIV/AIDS Legal Network.
5. Caplehorn, J. R., Lumley, T., Irwig, L., & Saunders, J. (1998). Changing attitudes and beliefs of staff working in methadone maintenance programs. Australian & New Zealand Journal of Public Health, 22, 505-508.
6. Crawford, M., Rutter, D., Manley, C., Weaver, T., Bhui, K., Fulop, N., et al. (2002). Systematic review of involving patients in the planning and development of healthcare. British Medical Journal, 325, 1263-1267.
7. Darke, S., Topp, L., & Ross, J. (2002). The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug and Alcohol Review, 21, 27-32.
8. Drugs & Poisons Regulations Group (2006). Policy for maintenance pharmacotherapy for opioid dependence. Melbourne, Australia: Department of Human Services.
9. Fischer, B., Chin, A., Kup, I., Kirst, M., & Vlahov, D. (2002). Canadian illicit opiate users' views on methadone and other opiate prescription treatment. Substance Use and Misuse, 37, 495-522.
10. Fraser, S. (2006). The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects. International Journal of Drug Policy, 17, 192-202.
11. Grbich, C. (1999). Qualitative research in health: An introduction. Sydney, Australia: Allen & Unwin.
12. Hamner, K. (1992). Gay-bashing: A social identity analysis of violence against lesbians and gay men. In G. Herek & K. Berrill (Eds.), Hate crimes: Confronting violence against lesbians and gay men. Newbury Park, CA: Sage.
13. Hopwood, M., Southgate, E., Kippax, S., Bammer, G., Isaac-Toua, G., & MacDonald, M. (2003). The injection of methadone syrup in New South Wales: Patterns of use and increased harm after partial banning of injecting equipment. Australian and New Zealand Journal of Public Health, 27, 551-555.
14. Jones, S., Power, R., & Dale, A. (1994). The patients' charter: Drug users' views on the 'ideal' methadone programme. Addiction Research, 1, 323-334.
15. Lintzeris, N., Lenne, M., & Ritter, A. (1999). Methadone injecting in Australia: A tale of two cities. Addiction, 94, 1175-1178.
16. Magura, S., Nwakeze, P. C., & Demsky, S. (1998). Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction, 93, 51-60.
17. Magura, S., Nwakeze, P. C., Kang, S.-Y., & Demsky, S. (1999). Program quality effects on patient outcomes during methadone maintenance: A study of 17 clinics. Substance Use and Misuse, 34, 1299-1324.
18. Montagne, M. (2002). Appreciating the user's perspective: Listening to the 'Methadonians'. Substance Use and Misuse, 37, 565-570.
19. National Treatment Agency for Substance Misuse (2001). Corporate strategy 2002-2005: More treatment, better treatment, fairer treatment. London: National Treatment Agency for Substance Misuse.
20. National Treatment Agency for Substance Misuse (2004). Making a difference to drug treatment services: Notable examples of user and carer involvement. London: National Treatment Agency for Substance Misuse.
21. National Treatment Agency for Substance Misuse (2005). User and carer involvement: Guidance notes to adult drug treatment plan 2006/07. London: National Treatment Agency for Substance Misuse.
22. Neale, J. (1998). Drug users' views of prescribed methadone. Drugs: Education, Prevention & Policy, 5, 33-45.
23. Neale, J. (1999a). Drug users' views of substitute prescribing conditions. International Journal of Drug Policy, 10, 247-258.
24. Neale, J. (1999b). Understanding drug-using clients' views of substitute prescribing. British Journal of Social Work, 29, 127-145.
25. NSW Health Department (1999). NSW methadone maintenance treatment clinical practice guidelines. Sydney, Australia: NSW Health Department.
26. Pani, P., & Pirastu, R. (2000). Take-home and compliance with methadone maintenance treatment. Heroin Addiction and Related Clinical Problems, 2, 33-38.
27. Psychogios, C., & Bareja, M. (2005). Alcohol and other drug treatment services in Australia 2003-04 (Drug Treatment Series Number 4). Canberra, Australia: Australian Institute of Health and Welfare.
28. Tajfel, H. (1981). Human groups and social categories. Cambridge, UK: Cambridge University Press.
29. Teesson, M., & Proudfoot, H. (Eds.). (2003). Comorbid mental disorders and substance use disorders: Epidemiology, prevention and treatment. Canberra, Australia: Australian Government Department of Health and Ageing.
30. Treloar, C., Abelson, J., Cao, W., Brener, L., Kippax, S., Schultz, L., et al. (2004). Barriers and incentives to treatment for illicit drug users. Canberra, Australia: Commonwealth Department of Health and Ageing.
31. Tritter, J., & McCallum, A. (2006). The snakes and ladders of user involvement: Moving beyond Arnstein. Health Policy, 79, 156-168.
32. Victorian Government Department of Human Services (2005). Consultation paper: Participation in your health service system; Victorian consumers, carers, and the community working together with their health service and the Department of Human Services. Melbourne, Australia: Victorian Government Department of Human Services.
33. Vormfelde, S., & Poser, W. (2001). Death attributed to methadone. Pharmacopsychiatry, 34, 217-222.
34. Wilkinson, R. (1999). Putting the picture together: Prosperity, redistribution, health and welfare. In M. Marmot & R. Wilkinson (Eds.), Social determinants of health. Oxford, UK: Oxford University Press.
35. Willke, R., Burke, L., & Erickson, P. (2004). Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels. Controlled Clinical Trials, 25, 535-552.
36. Wodak, A. (2006). All drug politics is local. International Journal of Drug Policy, 17, 83-84.
37. Wodak, A., Lynch, P., & Crofts, N. (2004). Is lawful discrimination against illicit drug users acceptable? Medical Journal of Australia, 180, 405-407.
38. World Health Organization (2003). Advocacy in mental health. Singapore: World Health Organization.